AltaThera Pharmaceuticals at HRS 2024

AltaThera HRS 2024 763 Sotalol IV

Chicago, IL – May 15, 2024 – AltaThera Pharmaceuticals will showcase its antiarrhythmic product, Sotalol IV, at the upcoming Heart Rhythm 2024 annual meeting in Boston, Massachusetts from May 16-19. Serving as a hub for innovation, discovery, and connection, HRS brings the world of electrophysiology together with over 8,500 attendees from around the world.

Sotalol IV’s rapid 1-hour loading dose allows healthcare practitioners to quickly assess a patient’s response to sotalol at chosen therapeutic levels and potentially reduce patient length of stay and increase bed availability at their institutions.

Attendees will be able to learn more about intravenous sotalol at the May 17 poster presentation, “Correlation of Mobile ECG with 12-Lead ECG Findings During Intravenous Sotalol Loading for Atrial Fibrillation”, authored by Benjamin A. Steinberg, MD, MHS et al. at the Abstract Pavilion. For more information about this poster and the conference program, please visit the Heart Rhythm 2024 website at

To hear more about the latest clinical data on Sotalol IV, come by booth 763 at HRS 2024 in Boston or visit our website at

About Sotalol IV

Sotalol IV is an antiarrhythmic indicated for:

  • The maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation / atrial flutter in patients with symptomatic AFIB/AFL] who are currently in sinus rhythm.
  • The treatment of life-threatening ventricular tachycardia.

About AltaThera

AltaThera is a precision medicine company using innovative science to improve patient care and solve serious and costly problems. AltaThera’s aim is to narrow the gap between scientific innovation and clinical decision-making by individualizing drug treatment so that the right patient can receive the right dose at the right time. AltaThera is based in Chicago, Illinois, USA. For more information, visit


Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 09/2023.

Please see Sotalol IV Highlights of Prescribing Information and full Prescribing Information at, including boxed warning, contraindications, and dosing.


SIV Highlights 09.2023